Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine Glucuronide SCHEMBL612431 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL17302928 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL152647 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL12082244 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL1743681 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13267437 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13268600 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13245908 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL5674614 | 0.99 | OPRM1 (0.98) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL5674692 | 0.97 | OPRM1 (0.94) | OPRM1MRGPRX2OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737518-B1 | REACTING 4,5-EPOXYMORPHINAN-6-OLS WITH BROMOGLUCURONIDES IN THE PRESENCE OF ZINC BROMIDE; DEPROTECTING END PRODUCTS TO MAKE MORPHINE-6-BETA-D-GLUCURONIDE (M6G) | CENES LIMITED (GB) | 2004-05-18 | — | — | US | disclosed |
| US-20040053854-A1 | Process for preparation of 4,5-Epoxymorphinan-6-oxyglucuronides | CENES LIMITED (GB) | 2004-03-18 | — | — | US | disclosed |
| EP-1077985-A1 | PROCESS FOR PREPARATION OF 4,5-EPOXYMORPHINAN-6-OXYGLUCURONIDES | CeNes Limited (GB) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058545-A1 | PROCESS FOR PREPARATION OF 4,5-EPOXYMORPHINAN-6-OXYGLUCURONIDES | CENES LIMITED (GB) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053854-A1 | Process for preparation of 4,5-Epoxymorphinan-6-oxyglucuronides | OGFR, OSTC, GALE | OPRM1 4/4885MRGPRX2 399/4885OPRD1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.